STARmed Thyroid RFA

Non-scarring. Incision-free. Thyroid preserving

Unlock a new possibility for thyroid nodules

STARmed Thyroid Radiofrequency Ablation (RFA) was first introduced in 2002 in Seoul, South Korea. Today, with over 94+ clinical articles worldwide demonstrating the efficacy of this minimally invasive treatment, STARmed is leading the world with our cutting-edge thyroid RFA technology.

20 million1

Americans have some form of thyroid disease, with the vast majority identified as benign lesions.


thyroid operations are performed each year in the United States.


thyroid resections are performed for benign diseases where patients could benefit from a less invasive option.

Continuance Mode

The Continuance Mode of the VIVA combo RF Generator produces radiofrequency (RF) output constantly throughout the procedure while automatically adjusting the amount of energy applied to the targeted nodule according to real-time impedance feedback. This innovative mechanism ensures the procedure’s safety by minimizing undesired tissue over-ablation.

Star RF Electrode

The monopolar star RF Electrode stands out as the first thyroid-dedicated RF electrode in the market. It is uniquely designed with a shorter shaft length of 7 or 10 cm to accommodate the gland’s superficial location and a thinner shaft of 18 or 19 gauge for enhanced energy control. It comes with an array of active tip lengths at 4mm, 5mm, 7mm, and 10mm to cater to different nodule sizes.

VIVA II RF Electrode

The monopolar VIVA II RF Electrode is the latest innovation in RF ablation. It is the first of its kind, featuring an adjustable active tip ranging from 5mm to 30mm to accommodate multiple large nodules of varying sizes with one electrode in one session. Its latest sharp technology ensures a smooth puncture, while the smaller handle allows for greater precision control.

Moving-shot technique

The Continuance Mode and the unique design of the STARmed RF Electrodes enable the Moving-Shot technique, which promotes ablation in units to limit thermal damage to surrounding tissue.

Play Video

Before STARmed
Thyroid RFA

6 months after
STARmed Thyroid RFA

Individual results may vary.
Photo courtesy of Dr. Jung Hwan Baek

Evidence-based procedure

According to a multi-institutional cohort study of thyroid nodules treated with RFA between July 2019 and January 2022, the median volume reduction rate (VRR) at 6 and 12 months were 73% and 76%, respectively. 4

Training opportunity

STARmed America is committed to refining the customer learning journey. We provide structured and measured procedure training programs for physicians and your care team.


The VIVA combo RF System is FDA-cleared and intended for use in percutaneous and intraoperative coagulation and ablation of tissue.

  1. General Information/Press Room.” American Thyroid Association, Accessed Apr 10, 2023.
  2. Kuo, J. H., McManus, C., & Lee, J. A. (2022). Analyzing the adoption of radiofrequency ablation of thyroid nodules using the diffusion of innovations theory: Understanding where we are in the United States? Ultrasonography, 41(1), 25–33.
  3. Park HS, Baek JH, Park AW, Chung SR, Choi YJ, Lee JH. Thyroid Radiofrequency Ablation: Updates on Innovative Devices and Techniques. Korean J Radiol. 2017;18(4):615-623. doi:10.3348/kjr.2017.18.4.615
  4. Kandil E, Omar M, Aboueisha M, et al. Efficacy and Safety of Radiofrequency Ablation of Thyroid Nodules: A Multiinstitutional Prospective Cohort Study. Ann Surg. 2022;276(4):589-596. doi:10.1097/SLA.0000000000005594